secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2026-08-05T13:28:46+00:00
Accession:  0001213900-26-085434
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports 78% QoQ increase in new institutions ordering LYMPHIR; vials up 31%
--------------------------------------------------------------------------------

- New institutional accounts ordering LYMPHIR increased 78% QoQ; total institutions now 42.
- Vials ordered by institutions rose 31% during quarter ended June 30, 2026.
- LYMPHIR has near-universal payer coverage; initial CTCL market exceeds $400M.
- Company expects >20 additional institutions in current quarter, targeting 100 priority institutions by year-end.
- Wholesaler orders have begun to reflect increased demand; revenue recognized on wholesale orders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026085434/0001213900-26-085434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026085434/ea0300371-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-085434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer